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1  | INTRODUC TION
Although classical techniques for diagnosis of disease-causing 
pathogens affecting both humans and animals most certainly still 
have their place, molecular tools, such as next generation sequenc-
ing (NGS), are proving invaluable for both disease diagnosis and con-
trol. Such is the case for the poxviral pathogen of cattle, lumpy skin 
disease virus (LSDV). Since its first isolation in South Africa in 1944, 
an extensive collection of epidemiological, diagnostic, control and 
genetic data relating to the virus and disease has been assimilated 
globally. This is largely attributed to the recent and rapid spread of 
the disease, previously thought to be confined to Africa, the Middle 
East, Eastern European countries and Asia (Sprygin, Artyuchova, 
et al., 2018; Vidanović et al., 2016). New outbreaks in these re-
gions prompted the full genome sequencing of LSDV isolates col-
lected in Greece (Agianniotaki, Mathijs, et al., 2017), Serbia (Toplak 
et al., 2017), Dagestan in Russia (Sprygin, Babin, et al., 2019), and an 
lumpy skin disease (LSD) vaccine virus during an active vaccination 
campaign in Croatia (Lojkic, Simic, Kresic, & Bedekovic, 2018). This 
significantly increased the existing full genome sequence data set of 
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Abstract
South Africa is endemic for lumpy skin disease and is therefore reliant on various live 
attenuated vaccines for the control and prevention of the disease. In recent years, 
widespread outbreaks of vaccine-like strains of lumpy skin disease virus (LSDV) were 
reported internationally, leading to an increase in the generation of full genome se-
quences from field isolates. In this study, the complete genomes of six LSDVs submit-
ted during active outbreaks in the 1990s in South Africa were generated. Based on 
phylogenetic analysis, the six viruses clustered with vaccine strains in LSDV Subgroup 
1.1 and are subsequently referred to as vaccine-associated. The genetic differences 
between the phenotypically distinct vaccine and vaccine-associated strains were 67 
single nucleotide polymorphisms (SNPs). This study characterized the location and 
possible importance of each of these SNPs in their role during virulence and host 
specificity.
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field isolates, viz. isolate NI-2490 (Kenya; 1958) (Tulman et al., 2001) 
and isolate Warmbaths (South Africa; 1999; Kara et al., 2003).
A live attenuated virus (LAV) was generated in 1963 in South 
Africa at the Onderstepoort Veterinary Research Institute by se-
rial passage of a Neethling-type field LSDV in cell culture and on 
the chorioallantoic membranes of embryonated hen's eggs, with in 
vivo trials in cattle proving its safety and efficacy for use as a vac-
cine (Weiss, 1968). Regular and widespread use of the commercial 
formulation of this vaccine was effective in reducing the number 
of LSD outbreaks in subsequent years, especially in controlling 
the disease in endemic areas (Hunter & Wallace, 2001). However, 
more recently, linked to this vaccine and related LSD vaccines, 
certain shortcomings have been reported (e.g. lack of DIVA ca-
pabilities, severe post-vaccination reactions and recombination 
with virulent field viruses) (Sprygin, Babin, et al., 2018). Protection 
against LSD is achieved by use of one of the commercially avail-
able Neethling-type LAV strains, or by use of attenuated sheep-
pox or goatpox vaccine viruses (Coetzer, Tuppurainen, Babiuk, & 
Wallace, 2018; Gari et al., 2015; Kitching, 2003). Complete ge-
nome sequences of the commercially available Neethling-type 
LAV strains of LSDV have been generated and submitted to the 
publicly accessible GenBank database (Douglass, van Der Walt, 
Omar, Munyanduki, & Williamson, 2019; Kara et al., 2003; Mathijs 
et al., 2016). Based on restriction fragment length polymorphism 
comparisons and subsequently, full genome sequencing of the 
Kenyan sheep- and goat-pox O-240 vaccine strain, it was eluci-
dated that this strain was originally derived from a Neethling-type 
LSDV (Black, Hammond, & Kitching, 1986; Tulman et al., 2001; 
Vandenbussche et al., 2016).
Various studies have been conducted to investigate the genome 
differences between virulent and vaccine LSDV strains in order to 
elucidate the genetic changes that result in the attenuation pheno-
type of the latter (Biswas et al., 2019; Douglass et al., 2019; Kara 
et al., 2003). With the exception of the single change in the superox-
ide dismutase (SOD) gene homolog encoded by LSDV ORF LW134 
described by Douglass et al. (2019), all other studies have identified 
multiple open reading frames (ORFs) with both alternative reading 
frames and numerous single nucleotide differences, which may con-
tribute to the attenuated phenotypes observed. Based on all the 
genetic differences between attenuated and virulent viruses, it is 
evident that multiple genes are involved and work in synergism to 
achieve host-specific attenuation. Currently, the number of known 
genetic differences that could be targeted during genomics-guided 
genetic engineering in development of a DIVA-compliant, safe and 
effective recombinant LSD vaccine is vast and it would be costly 
and time-consuming to evaluate them all using current technologies 
(Boshra et al., 2015).
Despite the tremendous success and effectiveness of using 
LAVs in preventing and controlling LSD, they have several inher-
ent limitations (Hunter & Wallace, 2001; Klement et al., 2018). It 
is currently impossible to serologically differentiate between vac-
cinated animals and those showing seroconversion due to natural 
infection, leading to the development of various molecular tests 
capable of distinguishing between LAVs and naturally occur-
ring field viruses (Agianniotaki, Chaintoutis, et al., 2017; Erster 
et al., 2019; Menasherow et al., 2014; Möller et al., 2019; Sprygin, 
Byadovskaya, et al., 2019). These tests are particularly important 
for use in countries non-endemic for LSD, where use of vaccination 
may be prohibited and presence of any seropositive cases may lead 
to trade embargoes, etc. In addition, there is a growing body of 
evidence that LSD LAVs are undergoing reversion to virulence by 
either recombining with virulent field strains or through mutations 
in unstable genomic regions leading to full-length gene restitution 
(Douglass et al., 2019). This shortcoming of LAVs is the reason why 
certain countries prohibit the use of commercial vaccines based on 
LAVs, but rather encourage control campaigns using inactivated, 
killed or heterologous vaccines. Outbreaks of severe LSD occurred 
in Russia in 2017, and the causative agents were identified to be ge-
netically similar to the commercially available LAV strains (Kononov 
et al., 2019; Sprygin, Babin, et al., 2018). One virulent isolate from 
Saratov in Russia was identified as a multiple intragenic recombi-
nant between commercially available Neethling-attenuated vac-
cine virus and the Kenyan sheep- and goat-pox O-240 vaccine 
(Sprygin, Babin, et al., 2018). Since the exact cause of attenuation 
of the virus during cell culture adaptation is not known, the rever-
sion of LAVs to virulent viruses is a major safety concern during 
vaccination campaigns (Tuppurainen et al., 2018). Even though 
South Africa is endemic for LSD, vaccination with either one of the 
commercial live attenuated Neethling-type vaccines is advised, but 
not compulsory, while none of the heterologous vaccines are com-
mercially available due to freedom from their respective parental 
viruses. Since vaccination is not compulsory in South Africa, the 
true extent of the number of animals vaccinated, the frequency of 
vaccination or which commercial vaccine was used on each farm 
or location is not known. Similarly, since not all suspected cases 
of LSD are laboratory confirmed, the true extent of wild-type or 
vaccine-related viruses circulating in South Africa is not known. 
Based on the observations in Europe and Russia of LAV vaccine 
strains involved in either reversion to virulence or recombination, 
it became essential to start investigating field isolates submitted in 
South Africa using full genome sequencing to identify the occur-
rence of similar events.
Phylogenetically, a clear distinction is observed between LSD 
vaccine viruses (Subgroup 1.1) and wild-type viruses (Subgroup 
1.2) as illustrated by Biswas et al. (2019). In this study, the com-
plete genomes of six LSDVs were determined using NGS tech-
nologies. These viruses were obtained from clinical samples 
submitted during active LSD outbreaks in the Republic of South 
Africa between 1991 and 1997. They were submitted from three 
provinces and clustered phylogenetically with the vaccine LSDVs. 
One of the six vaccine-associated viruses sequenced in this study, 
LSD-248/93, has frequently been shown to elicit LSD clinical 
symptoms in animals and is therefore considered to be a virulent 
LSDV (Annandale, Holm, Ebersohn, & Venter, 2012; Tuppurainen 
et al., 2010, 2012, 2013). Since these virulent viruses clustered 
phylogenetically with the vaccine Subgroup 1.1, it was important 
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to investigate nucleotide differences between them and the LAV 
strains. Various other studies have identified specific ORFs and 
their possible role in virulence, and while certain of these ORFs 
have been identified in this study, it is not true for others (Biswas 
et al., 2019; Douglass et al., 2019; Erster et al., 2019). The aim of 
this study was to investigate each of the observed nucleotide dif-
ferences in order to predict their possible role in virulence.
2  | MATERIAL S AND METHODS
2.1 | Virus strain culture, DNA isolation and 
sequencing
Information concerning the place of origin, year submitted and pas-
sage history of each of the viruses sequenced during this study 
are indicated in Table 1. Clinical samples were submitted to the 
University of Pretoria's Faculty of Veterinary Science for laboratory 
confirmation of suspected LSD outbreaks. Samples testing PCR-
positive for LSDV according to the method of Ireland and Binepal 
(1998) were subjected to virus isolation on cell culture.
2.1.1 | Virus isolation
The isolates, as listed in Table 1 (LSD-103/91, LSD-58/93, LSD-220-
1/93, LSD-220-2/93, LSD-248/93 and LSD-148/97), include their 
place of origin, year submitted and passage history. The viruses, LSD-
103/91, LSD-58/93, LSD-220-1/93, LSD-220-2/93 and LSD-148/97, 
were isolated from tissue samples as described below (Tuppurainen, 
Venter, & Coetzer, 2005). The tissue samples were homogenized in 
PBS, followed by centrifugation at 2,000 rpm for 10 min (min). The 
supernatant was collected, and 500 µl of this supernatant was used 
to inoculate monolayers of primary bovine dermis (BD) cells. For 
virus isolation from heparin blood samples, isolate LSD-248/93 was 
obtained from a heparin blood sample which was inoculated directly 
onto the monolayer of BD cells. The cells were prepared in 25 cm2 
flasks, using Eagles MEM containing 5% foetal bovine serum (FBS) 
and 1 mg/ml gentamicin. After 24 hr, the cells were washed with 
PBS and fresh medium containing 2% FBS added. The flasks were 
incubated at 37°C for 14 days and observed daily for CPE. If no CPE 
was detected after this time, a blind passage was done onto fresh BD 
cells. The BD cells were prepared in 75 cm2 flasks, using Eagles MEM 
(Lonza) containing 10% FBS (OBP), 1 × GlutaMAX™ Supplement 
(Gibco) and 1 × antibiotics (100 µg/ml penicillin, 100 µg/ml strep-
tomycin and 250 µg/ml amphotericin [Lonza]). Once the cells were 
80%–90% confluent, an aliquot of an LSDV isolate was then added 
to them for infection. The flasks were rotated every 20 min for 1 hr. 
Thereafter, the medium was removed and replaced with fresh me-
dium containing 2% FBS, 1 × GlutaMAX™ Supplement and 1 × an-
tibiotics. The flasks were incubated at 37°C with 5% CO2 until 90% 
CPE was observed.
2.1.2 | Viral DNA purification
The isolates were obtained from the University of Pretoria and used 
for full-length genome sequencing. All were passaged once more on 
BD cells as described above, prior to three freeze–thaw cycles at 
−20°C. The medium containing the lysed cells and virus was then col-
lected and subjected to sonication at 35 kHz for 10 min in a cooled 
water bath sonicator (Sonorex TK52, Bandelin, Germany). The tubes 
were then spun at 2,800 g for 5 min at 4°C. The supernatant was 
removed and kept on ice. The remaining pellet was re-suspended 
in 3 ml of 1 × PBS (without Ca+ and Mg+) (Sigma) by vortexing the 
mixture, followed by sonication at 35 kHz for 5 min and then spun 
at 2,800 g for 5 min at 4°C. The pellet was discarded and the result-
ing supernatant pooled with the earlier supernatant containing virus, 
and then transferred to an Oakridge tube. The tubes were spun at 
19 000 g for 60 min at 4°C. The supernatant was discarded, and the 
remaining pellet was re-suspended in 500 µl of 1 × PBS. The 500 µl 
was then used for the extraction of viral DNA using the Invitrogen 
PureLink™ Viral RNA/DNA Mini Kit (Life Technologies) as per the 
manufacturer's instructions. The samples were eluted in 50 µl of 
nuclease-free water and the viral DNA stored at –80°C prior to 
sequencing.
TA B L E  1   Lumpy skin disease viruses sequenced during this study
Isolate name
Reference in 







LSD-103-GP-RSA-1991 LSD-103/91 Onderstepoort, Gauteng, 
RSA
1991 #2 MN636839
LSD-58-LP-RSA-1993 LSD-58/93 Polokwane, Limpopo, RSA 1993 #3 MN636838
LSD-220-1-NW-RSA-1993 LSD-220-1/93 Potchefstroom, North West, 
RSA
1993 #1 MN636841
LSD-220-2-NW-RSA-1993 LSD-220-2/93 Potchefstroom, North West, 
RSA
1993 #1 MN636842
LSD-248-NW-RSA-1993 LSD-248/93 Potchefstroom, North West, 
RSA
1993 #4 MN636840
LSD-148-GP-RSA-1997 LSD-148/97 Onderstepoort, Gauteng, 
RSA
1997 #2 MN636843
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2.1.3 | Next Generation Sequence analysis and 
genome annotation
Extracted DNA was submitted for NGS Illumina sequencing to the 
Agricultural Research Council-Biotechnology Platform (ARC-BTP) 
using the Nextera DNA library kit from Illumina on the HiSeq 2000 
Illumina Sequencer. Between 0.5 and 2 Gb of HiSeq data was gen-
erated per sample. The HiSeq-generated paired-end reads were 
imported to CLC Genomics Workbench version 9.5., trimmed for 
quality by removing low-quality reads (quality limit = 0.05) and 
Illumina adaptor sequences. The remaining sequences were de novo 
assembled into contigs, as well as mapped against the published 
reference sequence of KX764645_Neethling-LSD-Vaccine-OBP 
and AF409137_Neethling-LSD-Warmbaths-RSA-2000. The consen-
sus sequence of each assembly and mapping was used to generate 
a single full genome consensus sequence. The newly constructed 
consensus sequences were aligned to 14 published LSDV complete 
genome sequences, and a maximum likelihood phylogenetic tree 
was constructed under GTR (G + I, G = 4) with 1,000 bootstrap it-
erations using mega 6 (Tamura et al., 2011). The aligned nucleotide 
sequences were used to calculate the pairwise distances between 
each sequence and to identify single nucleotide polymorphisms 
(SNPs) between the vaccine and vaccine-associated virus genomes. 
The new consensus sequences were annotated according to either 
the reference AF409137_Neethling-LSD-Warmbaths-RSA-2000 or 
KX764645_Neethling-LSD-Vaccine-OBP sequences. The annotated 
sequences generated during this study were deposited in GenBank 
with accession numbers indicated in Table 1.
2.1.4 | Genome comparison and protein domain 
predictions
A second alignment was generated containing the six vaccine-
associated, four vaccine sequences (KX764645_Neethling-LSD-
Vaccine-OBP, KX764643_Neethling-LSD-Vaccine- SIS-Lumpyvax, 
MK441838_Neethling-LSD-Vaccine-Herbivac- batch008 and 
KX764644_Neethling-LSD-Vaccine-Herbivac) and an isolate from 
a recently vaccinated animal MG972412_ Neethling-LSD-Cro2016-
Croatia-2016 (Lojkic et al., 2018). The 5′ and 3′ UTR regions were 
removed in order for the alignment to start at 91bps downstream of 
LW001 and end 7bps upstream of LW156. The sizes of each sequence 
in the alignment differ between 150,379 and 150,394. The number 
and position of each SNP between the vaccine and vaccine-associated 
viruses were determined. The influence of each SNP on the reading 
frame or predicted amino acid (aa) exchange was determined and de-
scribed in this study as either altering the reading frame, synonymous, 
non-synonymous SNP or within the intragenic regions. Predicted 
ORFs with changes in reading frames or synonymous SNPs were 
translated using CLC Genomics Workbench version 9.5, and the puta-
tive aa sequences were analysed using the InterPro domain and pro-
tein family classification program from the European Bioinformatics 
Institute, Cambridge, GB (https://www.ebi.ac.uk/interpro).
2.1.5 | PCR and Sanger sequence confirmation
Six of the mutations identified which might alter the reading frame 
of a specific ORF were confirmed with PCR and Sanger sequencing. 
A 1:10 dilution of the gDNA samples submitted for NGS was used 
as template in six individual PCRs along with the primers listed in 
Table 2. Dreamtaq DNA polymerase master mix (Life Technology) 
was added to a 20 µl reaction with 0.25 µmol/L of each primer at 
an annealing temperature of 53°C for 45 cycles. An aliquot of the 
resulting amplicons was analysed using 1% agarose gel electropho-
resis, and the remainder of the reactions were submitted to Inqaba 
Biotechnical Industries (South Africa) for Sanger sequencing, using 
the primers incorporated during the generation of the amplicons. 
Sequence data were analysed and compared using CLC Genomics 
Workbench 9.5 (QIAGEN Aarhus, www.clcbio.com).
3  | RESULTS
3.1 | New LSDV genomes
The complete genome sequences of six additional LSDV isolates 
were determined and used in subsequent analysis. These viruses 
were submitted to the University of Pretoria, Faculty of Veterinary 
Science, for diagnostic confirmation of suspected outbreaks in 
South Africa. The submission dates varied from 1991 to 1997, and 
additional information concerning the origin, isolation and passage 
history of the viruses are described in Table 1. Between 3 × 106 and 
1.8 × 107 HiSeq-generated reads were used to de novo assemble 
the genomes as well as mapping back to the newly generated con-
sensus sequences. Since the HiSeq NGS technology generates short 
reads (125 × 125 bp), the inverted terminal repeat regions were 
excluded from downstream analysis. Genomes between 150,391 
and 150,430 bps were subsequently used to generate an alignment 
TA B L E  2   List of primers used during PCR and Sanger 
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and analyse the phylogenetic relatedness of the isolates. Based 
on a maximum likelihood phylogenetic tree, the six isolates (LSD-
103/91, LSD-58/93, LSD-220-1/93, LSD-220-2/93, LSD-248/93 
and LSD-148/97) clustered with the commercial vaccine strains, 
KX764645_Neethling-LSD-Vaccine-OBP, KX764643_Neethling-
LSD-Vaccine-SIS-Lumpyvax, and KX764644_Neethling-LSD-
Vaccine-Herbivac (Figure 1). A high percentage sequence identity 
was observed within each of the two subgroup clusters (Subgroup 
1.1 and 1.2). For example, the isolates within the vaccine cluster 
shared between 99.94% and 100% sequence identity between 
them, while the sequences in the wild-type cluster shared between 
99.86% and 100% sequence identity among themselves. In con-
trast, between 98.48% and 98.54% sequence identity were identi-
fied between isolates from the vaccine with the wild-type cluster. 
The differences in percentage sequence identity between the two 
subgroup clusters were due to between 2,200 and 2,255 nucleotide 
differences, resulting in aa or reading frame changes affecting 124 
of the 156 predicted ORFs. Based on the large number of SNPs and 
aa exchanges observed between the vaccine and wild-type clusters, 
the differences between the vaccine and the six newly sequenced 
vaccine-associated viruses were investigated for their possible role 
in virulence.
3.2 | Virulent vaccine-associated viruses
The six vaccine-associated viruses were isolated from clinical sam-
ples submitted as part of diagnostic testing for confirmation of 
LSD outbreaks. Isolate LSD-248/93 has been extensively used as 
a virulent virus in order to induce LSD-associated pathogenicity in 
animals towards a better understanding of the disease and control 
(Annandale et al., 2012; Tuppurainen et al., 2010, 2012, 2013). There 
were 67 SNPs identified between the vaccine and vaccine-associ-
ated viruses, and these were classified as follows: homopolymers in 
intragenic regions (n = 12); SNPs in intragenic regions (n = 6); SNPs 
altering the reading frame (n = 8); synonymous SNPs (n = 21); and 
non-synonymous SNPs (n = 20) (Tables 1–5). Individual mutations 
will be discussed based on the aforementioned classifications.
3.3 | Mutations altering the reading frame
Eight mutations were identified to alter the predicted reading frames 
of six ORFs (Table 3). Each of the 8 mutations was confirmed using 
PCR and Sanger sequencing of the six vaccine-associated isolates, 
wild-type Neethling-LSD-Warmbaths-RSA-2000 and Neethling-
LSD-Vaccine-OBP vaccine strain. With the exception of ORF 
LW019, each of the changes resulted in predicted proteins similar 
to the wild-type viruses. In LW019, both the vaccine and wild-type 
viruses were predicted to translate two individual proteins (LW019a 
and LW019b) of different sizes. The wild-type LW019b (264 amino 
acids) contained both the BTB/POZ and BTB/Kelch domains, while 
LW019a (290 aa) had the Kelch-type beta-propeller. In contrast, 
the vaccine virus produced a shorter LW019b (150 aa) containing 
only the BTB/POZ domain and a larger LW019a (440 aa) with both 
BTB/Kelch and Kelch-type beta-propeller domains (Figure 2a). The 
vaccine-associated viruses had an (A) nucleotide insertion compared 
to the vaccine genome, but similar to the wild-type viruses at aa po-
sition 124. This abolishes the truncation of LW019b at position 150 
and instead resulted in a reading frame that predictably encodes 
a single 569 aa protein (Figure 2a). This ORF LW019, producing a 
single protein, is unique to the vaccine-associated viruses described 
here. Another unique feature of the LW019 ORF from the vaccine-
associated viruses was a non-synonymous SNP located at position 
123, exchanging the aspartate (D) aa found in both vaccine and viru-
lent viruses with asparagine (N) (Figure 2a). The D123N exchange 
occurs at the start of the BTB-Kelch domain, yet the influence of this 
exchange on the function of the protein is not known.
F I G U R E  1   Maximum likelihood 
phylogenetic analysis of new LSDV 
genomes (marked with black dots) in 
relation to sequences obtained from 
GenBank
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3.4 | Single nucleotide polymorphisms
The 21 synonymous SNPs between the vaccine and vaccine-associ-
ated viruses were detected in 20 ORFs (Table 5). Of the 21 SNPs, 13 
were unique to the vaccine-associated viruses and eight similar to 
the virulent wild-type viruses. The majority of these SNPs were lo-
cated in ORFs central to the LSDV genome. In contrast, 20 non-syn-
onymous SNPs in 18 ORFs were identified with nine of them unique 
to the vaccine-associated and 11 identical to the virulent wild-type 
viruses (Table 4). The non-synonymous mutations were equally dis-
tributed across the LSDV genome.
3.5 | Mutations within the intragenic regions
Twelve mutations associated with homopolymer repeat sequences 
and six additional SNPs were identified within the intragenic re-
gions of the vaccine-associated viruses. Of the 18 SNPs, 13 were 
identical to the wild-type viruses and the others unique to the 
vaccine-associated viruses (Table 6). The majority of the muta-
tions were insertions of a nucleotide within the vaccine-associated 
viruses.
4  | DISCUSSION
4.1 | Mutations altering the reading frame
Nine frameshift mutations were previously identified in vaccine and 
three in virulent LSDV genomes (Kara et al., 2003). In this study, 8 
mutations were identified that alter the reading frames of six ORFs 
(Table 3). Six of these ORFs (LW019, LW086, LW087, LW131 and 
LW134) were previously described by Kara et al. (2003), and every 
mutation observed here resulted in the alteration to a reading frame 
identical to the virulent wild-type virus, with the exception of the 
one identified within ORF LW019. In contrast to both wild-type and 
vaccine viruses, the newly described vaccine-associated strains have 
a single LW019 ORF, predicted to produce a single Kelch-like pro-
tein. Only isolate Neethling LSDV NI-2490-Kenya-1958 (AF325528) 
and its laboratory-derived strain KSGPO240 (KX683219) have a 
similar single predicted 569 amino acid protein.
The ORFs LW086 and LW087 both contain a Nudix hydrolase 
signature domain, found in the MutT proteins, similar to the vaccinia 
virus (VACV) D9 and D10 mRNA-decapping enzymes (Bessman, 
Frick, & O’Handley, 1996). Both these enzymes have been shown 
to play a role in the virulence of VACV by altering or inhibiting the 
expression of host proteins, through the degradation of mRNA by 
means of decapping the methylated cap attached to mRNA (Parrish 
& Moss, 2007). The two neighbouring proteins function in syner-
gism in order to down-regulate the host mRNA production, even 
though D9 is expressed early and D10 late during virus infection (Liu, 
Wyatt, Orandle, Minai, & Moss, 2014; Parrish, Resch, & Moss, 2007). 
Vaccine-associated and virulent wild-type viruses encode LW086 
ORFs of 213 and ORF LW087 of 253 aa, in contrast to the truncated 
versions in vaccine viruses of 210 and 200 amino acids, respectively 
(Figure 2b,c). Even though none of these truncations disrupted the 
predicted Nudix boxes, they would be predicted to alter the ter-
tiary five beta-stranded structure of LW086 and LW087 (Bessman 
et al., 1996) (Figure 2b,c). A non-synonymous substitution changed 
aa position 12 of LW087 from glycine (G) to an acidic aspartate 
(D) in both the virulent wild-type and vaccine-associated viruses 
(Figure 2c). The influence of this exchange on the biological function 
and cellular location of the protein is not known.
In contrast to the previous ORFs, LW114 was truncated at 168 
amino acids in the vaccine-associated and virulent wild-type viruses 
compared to the 179 aa protein of the vaccine strains (Figure 2d). 
The latter has an additional C-terminal sequence of IVKKPFKNNNG. 
LW114 encodes a ribonuclease H-like domain found in Holliday junc-
tion resolvases such as A22 of VACV, with which it has a 56% sequence 
identity. The vaccinia virus A22 has been shown to function as dimers 
during association with Holiday Junction DNA during the cleavage of 
such structures (Garcia, Otero, Lebowitz, Schuck, & Moss, 2006).
A significant change at aa position 83 of ORF LW131 in the 
vaccine-associated viruses abolished the truncation observed 
TA B L E  3   Mutations identified between vaccine strains and vaccine-associated viruses involved in altering the reading frame. The 
position of each SNP is provided for KX764645_Neethling-LSD-Vaccine-OBP and AF409137_Neethling-LSD-Warmbaths-RSA-2000
#











Amino acid position 
in protein
1 13,403 (–) A 13,412 (A) LW019 124
2 68,066 (A) – 68,095 (–) LW086 206
3 81,108 (T) C 81,131 (C) LW087 198
4 81,110 (T) A 81,133 (A) LW087 198
5 81,111 (T) – 81,134 (–) LW087 198
6 105,629 (A) – 105,695 (–) LW114 168
7 119,429 (–) T 119,523 (T) LW131 83
8 124,248 (A) – 124,343 (–) LW134 721
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in vaccine viruses (generating a 108 aa SOD), restoring the pro-
tein to its full length, as found for the virulent wild-type viruses 
(a 161 aa protein) (Figure 2e). Even though SODs are highly con-
served among pox viruses, it was the first VACV core protein de-
scribed not to play a role in virulence or virus replication (Almazan, 
Tscharke, & Smith, 2001). It is not yet clear if the large deletion 
within LW131 in the LSD vaccine viruses produces a functional 
SOD protein.
The last of the six predicted ORFs with an altered reading frame 
difference was LW134 (Table 3). The predicted protein is similar to 
the VACV serpin protein B22R, coding for a complete 2025 aa pro-
tein in the virulent wild-type viruses, and due to the reading frame 
shift a 2024, aa protein in the vaccine-associated viruses (Figure 2f). 
In contrast, the vaccine viruses are predicted to produce two pro-
teins, one of 721 amino acids containing the N-terminal domain and 
the larger, a protein of 1,243 amino acids inclusive of the C-terminal 
transmembrane and cytoplasmic regions (Figure 2f). Complete or 
partial deletion of the B22R homologues in other poxviruses has in-
dicated that it is nonessential for modulating the immune responses, 
yet it has anti-inflammatory and anti-apoptotic properties (Blake 
et al., 1995; Kettle, Blake, Law, & Smith, 1995; Legrand et al., 2005).
Two ORFs with alternative reading frames in both the vaccine 
and wild-type viruses (LW013 and LW026) remained unchanged in 
the vaccine-associated viruses. ORF LW144, with a truncation in the 
vaccine virus, also codes for two proteins in the vaccine-associated 
viruses, similar to the vaccine strains (Kara et al., 2003).
4.1.1 | Single nucleotide polymorphisms
Of the 41 SNPs within ORFs identified between the vaccine and 
vaccine-associated viruses, 21 were synonymous and 20 non-syn-
onymous. Although the synonymous SNPs are interesting for virus 
evolution, the focus of this study was to investigate the possible role 
non-synonymous SNPs and their resulting amino acid exchanges 
might have on virulence, and thus, only these will be discussed in 
more detail.
The first non-synonymous SNP unique to the vaccine-associated 
viruses was in LW011, the predicted G-protein-coupled chemokine 
receptor. This SNP resulted in an exchange of alanine (A) at position 
11 with aspartate (D). This substitution (A11D) occurred in the signal 
peptide region of the non-cytoplasmic N-terminal domain, essential 
TA B L E  4   Non-synonymous SNPs identified between vaccine strains and vaccine-associated viruses. Amino acid exchanges are listed as 
follows: vaccine virus (>) vaccine-associated virus. The position of each SNP is provided for KX764645_Neethling-LSD-Vaccine-OBP and 
AF409137_ Neethling-LSD-Warmbaths-RSA-2000
#


















1 8,074 (G) T 8,080 (G) LW011 11 A > D
2 13,408 (C) T 13,418 (C) LW019 123 D > N
3 18,562 (C) T 18,582 (C) LW026 121 A > T
4 19,534 (T) A 19,554 (T) LW027 438 K > N
5 21,567 (T) C 21,584 (C) LW028 135 T > A
6 47,010 (A) T 47,033 (T) LW052 33 N > K
7 50,168 (T) C 50,191 (C) LW057 272 I > V
8 71,040 (G) A 71,064 (G) LW079 128 R > K
9 77,038 (A) T 77,062 (T) LW083 663 K > N
10 80,547 (G) A 80,570 (A) LW087 12 G > D
11 81,255 (–) A 81,277 (A) LW087 C-Terminal: ->S: 
Same as wild type
12 81,258 (–) A 81,272 (A) LW087 C-Terminal: -> L: 
Same as wild type
13 91,639 (A) G 91,712 (G) LW098 652 I > T
14 91,925 (C) T 92,009 (T) LW098 553 G > D
15 104,904 (T) G 104,971 (G) LW112 347 S > R
16 135,777 (T) C 135,894 (T) LW144a 119 F > L
17a 136,177 (-) T 136,295 (T) LW144 L > FI
18a 136,177 (-) A 136,295 (–) LW144 L > FI
19a 136,177 (-) T 136,295 (–) LW144 L > FI
20 140,948 (T) C 140,999 (T) LW147 143 I > T
ªMutation confirmed with PCR and Sanger sequencing.
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for translocating the protein and its seven transmembrane regions 
to the cell membrane (Figure 3a). The impact of this mutation on 
the translocation and subsequent functioning of the LSDV G-protein 
chemokine needs to be investigated. This unique mutation did not 
occur in the virulent vaccine-like strains identified during the 2017 
outbreaks in Russia (Kononov et al., 2019). Since this mutation does 
not occur in any of the other virulent LSDVs, the importance of it 
during virulent phenotype is questioned and should be elucidated.
Several hydrophobic–polar mutations were observed in LW026, 
LW028 and LW147 (Table 4). The A121T exchange in the Pox-F11 
Rho signalling inhibitor encoded for by ORF LW026 is unique to the 
vaccine-associated viruses. No additional information or domain pre-
dictions are available for this protein, and therefore, the impact of this 
mutation on virulent phenotype is not known. In contrast, the T135A 
exchange in the palmitylated extracellular enveloped virus membrane 
protein predicted for ORF LW028 is identical between the virulent 
wild-type and vaccine-associated viruses (Table 5). This protein has 
the characteristic multiple phosphatidylcholine-hydrolysing phospho-
lipase D (PLD) repeat domains (Koonin, 1996). The T135A mutation 
occurs within the first PLD4 catalytic motif, yet the influence of this 
single mutation on the virulent phenotype is not known (Figure 3b).
The neighbouring LW027 encodes for a 639 aa homologue of 
VACV F12 (Tulman et al., 2001). The latter is important in virion 
transport to the cell surface due to its kinesin light chain, and specif-
ically, the cargo-binding tetratricopeptide repeats (TPRs) contained 
therein (Morgan et al., 2010). A comparison between VACV-F12 and 
LW027 of LSDV shows conservation at the six TPRs and WD motif. 
The vaccine-associated viruses possess a unique aa exchange at po-
sition 438 of a positive lysine (K) to asparagine (N). This K438N is 
within the cargo-binding region, between TPR-5 and TPR-6, where 
LSDV has multiple consecutive positive amino acids compared to the 
VACV polar uncharged ones. The implication of this substitution on 
virion export function of the vaccine-associated viruses needs to be 
elucidated.
The ORF LW052 encodes a 110 aa protein, predicted 
to belong to the G3 family of pox virus proteins (Tulman 
et al., 2001). The exact function of this protein is unknown, 
but it is predicted to play a role in virus entry as a component 
of the entry-fusion complex through its association with L5 
(Wolfe & Moss, 2011). The protein has an N-terminal non-cy-
toplasmic domain followed by a transmembrane region, and 
from position 25 a cytoplasmic domain (Senkevich, Ojeda, 
Townsley, Nelson, & Moss, 2005). In the vaccine-associated 
and virulent wild-type viruses, a positive lysine (K) is located 
at position 33, compared to the uncharged asparagine (N) in 
the vaccine viruses (Table 4). This N33K aa exchange results 
TA B L E  5   Synonymous SNPs identified between vaccine strains and vaccine-associated viruses. The position of each SNP is provided for 
KX764645_Neethling-LSD-Vaccine-OBP and AF409137_ Neethling-LSD-Warmbaths-RSA-2000
#

















1 11,507 (C) T 11,512 (C) LW017 12 L = L
2 39,546 (T) C 39,567 (T) LW045 212 T = T
3 43,846 (T) C 43,866 (C) LW049 249 G = G
4 56,951 (C) G 56,977 (C) LW066 60 A = A
5 61,240 (T) C 61,269 (T) LW071 416 G = G
6 64,167 (C) T 64,196 (T) LW072 68 S = S
7 71,998 (G) A 72,022 (G) LW083 572 A = A
8 81,723 (A) G 81,747 (A) LW088 488 P = P
9 85,571 (C) T 85,595 (T) LW090 65 A = A
10 85,990 (A) T 86,014 (A) LW091 85 S = S
11 87,868 (G) A 87,892 (A) LW094 441 G = G
12 103,332 (A) G 103,405 (A) LW111 60 S = S
13 104,442 (C) T 104,509 (T) LW112 193 P = P
14 109,433 (G) A 109,499 (G) LW116 863 L = L
15 109,664 (T) C 109,730 (T) LW116 940 G = G
16 118,583 (T) C 118,713 (T) LW129 61 D = D
17 125,940 (C) T 126,035 (T) LW135 231 S = S
18 131,803 (C) T 131,901 (T) LW144a 25 G = G
19 133,229 (T) C 13,332 (T) LW145 574 C = C
20 136,014 (A) G 136,132 (G) LW151 540 E = E
21 147,891 (A) T 147,946 (A) LW152 389 I = I
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in a significant increase in the predicted antigenicity profile of 
the region, using the algorithm described by Welling, Weijer, 
van der Zee, and Welling-Wester (1985; Figure 4). Of the 12 
known proteins involved in the virus entry-fusion complex, 
only LW052 was identified to differ between the vaccine-as-
sociated, virulent and vaccine viruses. The impact of this aa 
F I G U R E  2   Graphical representation of six LSDV ORFs and their predicted domains using InterProScan predictions based on VACV protein 
names and functionality, where known. The influence of each SNP on the reading frames of either vaccine, vaccine-associated or wild-type 
LSDVs is indicated. (a) ORF LW019. A complete 569 aa ORF is observed in the vaccine-associated strains, compared to the two individual ORFs 
(LW019a and LW019b) predicted for either the wild-type (AF409137_Neethling-LDS-Warmbaths-RSA-2000) or vaccine (KX764645_Neethling-
LSD-Vaccine-OBP) strains. (b) ORF LW086. This ORF within the vaccine-associated and virulent wild-type viruses is predicted to code for a 213 
aa protein, compared to a 210 aa truncated protein in the vaccine strain. (c) ORF LW087. Similar to LW086, the vaccine-associated and virulent 
wild-type ORFs are predicted to produce a 253 aa protein and the vaccine virus strain a truncated 200 aa protein. In addition, both the vaccine-
associated and wild-type viruses have a D at position 12 in the N-terminal domain, compared to the G of the vaccine virus. (d) ORF LW114. The 
vaccine virus predictably encodes a longer 179 aa protein, while both the vaccine-associated and wild-type viruses encode truncated 168 aa 
proteins. (e) ORF LW131. The vaccine-associated and wild-type viruses are predicted to code for a complete 161 aa superoxide dismutase-like 
protein, whereas for the vaccine viruses a termination signal leads to a shorter 108 amino acid protein. (f) ORF LW134. The wild-type virus is 
predicted to produce a complete 2025 aa protein, while the vaccine-associated viruses produced a 2024 aa protein, due to a deletion of the 
asparagine (N) at position 2020 (N2020del). By contrast, the vaccine virus should produce two proteins of 721 and 1,243 amino acids
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exchange in LW052 on virus entry or the functionality of the 
virus entry-fusion complex is not known.
Two conservative aa exchanges were observed in LW057 and 
LW079. The first was an isoleucine (I) exchange at the C-terminal aa 
position 372 of vaccine viruses to valine (V) in the vaccine-associated 
viruses. This V372I non-synonymous SNP was also observed for the 
virulent wild-type viruses (Table 4). The second exchange is of an 
arginine (R) at position 128 of LW079 within the vaccine viruses to a 
lysine (K) in the vaccine-associated viruses. This substitution and the 
resulting R128K aa exchange are unique to the vaccine-associated 
viruses (Table 4).
The VACV D5 protein is the product of one of three early 
viral genes constitutively expressed for its involvement in DNA 
synthesis (Traktman, Sridhar, Condit, & Roberts, 1984). It has an 
AAA + ATPase with both Walker A and B domains, as well as heli-
case motif C, belonging to the superfamily III (SFIII) helicase family 
(Evans, Klemperer, Ghosh, & Traktman, 1995). Various tempera-
ture-sensitive D5 mutants have been generated in this regard, and 
their functions in replication and recombination were determined 
(Evans & Traktman, 1992). Additional site-directed mutants involv-
ing D5 were produced to investigate the role these amino acids 
have on the structure and function of the protein (Boyle, Arps, & 
TA B L E  6   Mutations within the intragenic regions identified between vaccine strains and vaccine-associated viruses. The position of each 





















1 1,329 (–) A 1,349 (A) Homopolymer (Poly 
A = 9)
LW002 and LW003 Before LW002
2 8,160 (–) T 8,168 (T) Homopolymer (Poly 
T = 11)
LW011 and LW012 −56 before 
LW011
3 9,956 (–) A 9,960 (–) Homopolymer (Poly 
A = 9)
LW013 and LW014 −43 before 
LW013
4 10,753 (T) — 10,758 (T) Homopolymer (Poly 
T = 9)
LW015 and LW016 −28 before 
LW015
5 15,627 (–) T 15,644 (T) Indel LW022 and LW023 −144 before 
LW022
6 16,006 (–) A 16,025 (A) Homopolymer (Poly 
A = 8 – 10)
LW023 and LW024 −67 before 
LW023
7 16,006 (–) A 16,026 (A) Homopolymer (Poly 
A = 8–10)
LW023 and LW024 −67 before 
LW023
8 22,614 (A) G 22,632 (G) SNP LW029 and LW030 −6 before LW029






10 57,977 (–) T 58,006 (T) Homopolymer (Poly 
T = 7)
LW067 and LW068 −43 before 
LW068
11 110,317 (A) - 110,383 (A) Indel LW116 and LW117
12 113,978 (–) A 114,044 (A) Homopolymer (Poly 
A = 11)
LW122 and LW123 −21 before 
LW123
13 113,978 (–) A 114,045 (A) Homopolymer (Poly 
A = 11)
LW122 and LW123 −22 before 
LW123
14 122,088 (–) T 122,182 (T) Indel LW133 and LW134 −10 before 
LW134
15 122,088 (–) C 122,183 (C) Indel LW133 and LW134 −9 before LW134
16 122,088 (–) T 122,184 (T) Indel LW133 and LW134 −8 before LW134
17 139,041 (–) T Homopolymer (Poly 
T = 7)
LW145 and LW146 −180 before 
LW146
18 149,398 (T) (not OBP, 
but all other vaccine 
strains)
— 149,453 (T) Homopolymer (Poly 
T = 9)
LW154 and LW155
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Traktman, 2007). The closely related homologue of D5 in LSDV is 
encoded by ORF LW083. At position 663, the vaccine-associated, 
virulent wild type and VACV code for an asparagine (N), while the 
vaccine viruses code for a positive lysine (K) (Table 4). The major-
ity of the previously mapped mutations in D5 resulting in the tem-
perature-sensitive mutants were located in the N-terminal region, 
F I G U R E  3   Graphical representation of the predicted domains within five ORFs, based on InterProScan using VACV protein names and 
functions. The location of each observed non-synonymous SNP within these reading frames is indicated with an arrow at its position with 
the aa predicted in the genomes of the LSD vaccine viruses first and the aa exchange present in the vaccine-associated viruses second. (a) 
ORF LW011. The G-coupled chemokine receptor protein with N-terminal signal, transmembrane and non-cytoplasmic domains, followed 
by the G-coupled chemokine receptor domain with six intermitted transmembrane regions. (b) ORF LW028. This phosphatidylcholine-
hydrolysing phospholipase D (PLD) has the characteristic multiple PLD domains, with two PLD4 and one PLDc3 domain. (c) ORF LW083. The 
vaccinia D5 homologue has a C-terminal with AAA + ATPase, Walker A and B domains and a helicase motif C belonging to the superfamily 
III. (d) ORF LW144. In the wild-type virulent LSDV strain, a single 550 aa protein is encoded for. In contrast, the vaccine and vaccine-
associated viruses the reading frame is divided to encode two proteins, LW144a with either 269 or 270 amino acids and LW144b consisting 
of 281 amino acids. The Kelch-like proteins produced by the vaccine and vaccine-associated viruses are divided so that LW144a contains the 
BTB/POZ and BTB-kelch domains and LW144b the Kelch-like beta-propeller with four Kelch 1 repeat regions. (e) ORF LW147. The ankyrin 
repeat domain has seven ankyrin repeat regions followed by a PRANC C-terminal domain
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for which functionality has not yet been determined. The four 
conserved motifs (Walker A and Walker B boxes, motif C and the 
AAA + motif) and one of the previously mapped temperature-sen-
sitive mutations (Ets69) are all located in the C-terminal region, 
from position 490 onwards (Figure 3c). The K663N exchange oc-
curred in the C-terminal region, after the four conserved motifs 
and before the temperature-sensitive mutant Ets69 at position 
682 (Figure 3c). The impact of K663N on the biological or struc-
tural function of LW083 in LSDV needs to be investigated using 
site-directed mutagenesis. Previous studies showed that the VACV 
protein A20 interacts as the scaffold with D4, H5 and D5 to form a 
functional replication complex. The binding of A20 to D5 involves 
amino acids 201 to 251 of the A20 protein (Ishii & Moss, 2002). 
The LSDV homologue of A20 is encoded by the LW112 ORF, where 
both synonymous and non-synonymous SNPs were identified 
(Tables 4 and 5). The latter results from exchange of a positive ar-
ginine (R), observed at position 347 in vaccine-associated, virulent 
wild-type, VACV and certain LSDV vaccine strains, with a serine (S) 
in the KX764645_Neethling-LSD-Vaccine-OBP and MH646674_
LSD-Saratov-Russia-2017 viruses. Mutant VACV variants where 
the same positive region was substituted with alanine (A) resulted 
in viable viruses with no observable phenotypic changes (Punjabi 
et al., 2001). Therefore, the effect of this S347R mutation, as well 
as K663N in LW083, on the formation and functionality of the 
DNA replication complex needs to be investigated.
Transcription of early viral genes is dependent on the early 
transcription factor protein complex comprised of the 70 kDa 
small subunit of LW084 and the 82 kDa large subunit of LW098 (Li 
& Broyles, 1993; Tulman et al., 2001). The latter protein has two 
non-synonymous mutations at positions 553 and 652, both of which 
are identical in the vaccine-associated and virulent wild-type vi-
ruses, in comparison with the vaccine viruses. The vaccine strains 
have a glycine (G) at position 553, while the vaccine-associated vi-
ruses have negatively charged aspartate (D). The second mutation at 
position 652 exchanges a non-polar isoleucine in the vaccine viruses 
with a polar threonine (T) (Table 4). The importance of the LW098 
homologue in VACV, A8, during early transcription and virion mor-
phogenesis has been described (Hu, Wolffe, Weisberg, Carroll, & 
Moss, 1998), yet the impact of these mutations in LSDV is currently 
unknown and warrants further investigation.
As previously mentioned, ORF LW144 encodes for two overlap-
ping proteins, LW144a and LW144b (269/270 and 281 amino acids), 
in the vaccine and vaccine-associated viruses and a single 550 aa 
protein in the wild-type viruses (Figure 3d). The vaccine-associated 
viruses have a conservative aa exchange at position 119 of leucine 
(L) from phenylalanine (F), that is unique to this group of viruses. 
This exchange is located within the BTB-Kelch-like domain of the 
LW144a (Figure 3d). At position 252 of LW144a, the vaccine viruses 
have a leucine (L), while both the vaccine-associated and wild-type 
viruses have a phenylalanine (F) and an insertion of isoleucine (I). 
This insertion resulted in the vaccine-associated viruses encoding a 
270 aa LW144a in contrast to the 269 aa encoded by the vaccine 
viruses (Figure 3d). The L252FI exchange occurs between the BTB-
Kelch-like and Kelch-type beta-propeller domains, and therefore, 
the influence of this mutation is not known.
The last confirmed non-synonymous mutation was observed in 
ORF LW147, encoding a protein with predicted ankyrin repeat re-
gions. The aa exchange at position 143 is a polar threonine (T) from 
a non-polar isoleucine (I) in both the vaccine and wild-type viruses. 
This I143T exchange is unique to the vaccine-associated viruses and 
occurs between ankyrin repeat regions 3 and 4 (Figure 3e). Since this 
is a newly described exchange, the influence of it on the structure 
and function should be investigated.
4.1.2 | Mutations within the intragenic regions
The study identified 18 SNPs within intragenic regions, with 12 as-
sociated with homopolymer repeat sequences. The composition of 
homopolymers is difficult to determine accurately, irrespective of 
the sequencing technology or platform used. The combination of 
new NGS technologies and different error correction software tools 
F I G U R E  4   Graphical representation of the predicted domains present in LW052 and their relationship to the calculated antigenicity 
profiles based on the method of Welling. The antigenicity profile of AF409137_Neethling-LSD-Warmbaths-RSA-2000 is in blue, vaccine 
strain KX764645_Neethling-LSD-Vaccine-OBP in red and that of the vaccine-associated LSD-248-NW-RSA-1993 in black [Colour figure can 
be viewed at wileyonlinelibrary.com]
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aims at solving these problems. Since different methods were used 
to generate the consensus sequences for each of the viruses, each of 
the mutations was validated by visual inspecting the reads mapped to 
the position, rather than through Sanger sequencing. The mutations 
within the intragenic region were mostly indels and predominantly 
located in early promoter regions, thereby extending the promoter 
spacer length and possibly increasing the expression level of the 
ORFs under the control of these set promoters (Di Pilato, Sanchez-
Sampedro, Mejias-Perez, Sorzano, & Esteban, 2015). Expression of 
ORFs that might be affected by increased spacer regions is as fol-
lows: LW002, LW011, LW013, LW022, LW023, LW034, LW068, 
LW123, LW134 and LW146. In contrast, there are deletions of a sin-
gle nucleotide in the promoter regions of ORFs LW015 and LW155 of 
vaccine-associated viruses compared to certain vaccine strains.
5  | CONCLUSION
Since South Africa is endemic for LSD, it has utilized LAVs since the 
1970s to control major disease outbreaks. Annual vaccination of ani-
mals is advised, but is not obligatory, resulting in indeterminate data 
concerning the overall usage, frequency and circulation of LAVs in 
the animal population. Reports of ‘vaccine failures’ are received oc-
casionally, and thus, it is important to determine which factors may 
be at play, including genetic stability of field and vaccine strains. In 
order to fill this caveat, retrospective sequencing of the complete 
genomes of historic isolates of LSDV submitted during active out-
breaks is underway. This study introduced the complete genomes 
of six field-derived LSDVs, which clustered phylogenetically with 
the LAV viruses. The nucleotide differences between these virulent 
vaccine-associated and attenuated vaccine viruses were investi-
gated and their possible roles in virulence discussed. Of the 67 SNPs 
observed between the vaccine-associated and vaccine viruses, 40 
were identical to the virulent wild-type viruses. This 60% similarity 
to virulent phenotypes is indicative of selection-driven genetic drift. 
Since 31% of the mutations resulted in no aa exchanges, the remain-
ing SNPs were scrutinized for their possible role in virulence. Of the 
remaining 46 SNPs, 18 occurred in the intragenic regions and may 
play a role in the regulation of gene transcription and protein levels, 
leaving 28 non-synonymous SNPs in 17 ORFs as possible causes for 
the reversion of the attenuated phenotypes to virulence. These 17 
ORFs encode putative proteins involved in mRNA regulation, DNA 
synthesis, protein regulation, virus entry, cellular apoptosis, virion 
formation and transport. It is important that the role of each of these 
ORFs be investigated individually as well as in synergism for their 
potential role in virulence, and especially reversion to virulence from 
an attenuated phenotype.
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